Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Exon Recombination02:32

Exon Recombination

4.3K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.3K
Base Excision Repair01:54

Base Excision Repair

5.4K
5.4K
Base Excision Repair01:54

Base Excision Repair

27.3K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
27.3K
Gene Therapy00:59

Gene Therapy

27.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.9K
Gene Therapy00:59

Gene Therapy

4.7K
4.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.2K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Dynamic Reorganization of Developmental to Adult Genome Topology Controls the Initiation and Stabilization of the Human Muscle Stem Cell State.

bioRxiv : the preprint server for biology·2026
Same author

Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice.

Nature communications·2025
Same author

Old World alphaviruses use distinct mechanisms to infect brain microvascular endothelial cells for neuroinvasion.

Cell reports·2025
Same author

Macrophage-derived Spp1 promotes intramuscular fat in dystrophic muscle.

JCI insight·2025
Same author

DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function.

Nature communications·2025
Same author

Old World alphaviruses use distinct mechanisms to infect brain microvascular endothelial cells for neuroinvasion.

bioRxiv : the preprint server for biology·2025

Video Experimental Relacionado

Updated: Mar 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

Terapia de omisión de exones

Courtney S Young1, April D Pyle2

  • 1Molecular Biology Interdepartmental Program, Center for Duchenne Muscular Dystrophy, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095.

Cell
|November 19, 2016
PubMed
Resumen
Este resumen es generado por máquina.

Exondys 51 es la primera terapia aprobada por la FDA para la distrofia muscular de Duchenne (DMD), dirigida al exón 51 para restaurar el marco de lectura en pacientes elegibles. Este tratamiento utiliza la expresión de distrofina como un marcador sustituto para la eficacia.

Más Videos Relacionados

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

Videos de Experimentos Relacionados

Last Updated: Mar 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

Área de la Ciencia:

  • La bioquímica
  • La genética
  • Neurología

Sus antecedentes:

  • La distrofia muscular de Duchenne (DMD) es un trastorno genético progresivo.
  • Los tratamientos actuales para la DMD son limitados, lo que requiere nuevos enfoques terapéuticos.

Objetivo del estudio:

  • Introducir Exondys 51 (eteplirsen) como un nuevo tratamiento para la distrofia muscular de Duchenne.
  • Para resaltar el mecanismo de acción y la aprobación reglamentaria de Exondys 51.

Principales métodos:

  • Exondys 51 emplea oligonucleótidos antisenso para atacar y omitir el exón 51 en el gen de la distrofina.
  • Este salto de exones tiene como objetivo restaurar el marco de lectura y permitir la producción de una proteína distrofina acortada.

Principales resultados:

  • Exondys 51 recibió una aprobación acelerada de la FDA basada en los niveles de expresión de distrofina.
  • El tratamiento está indicado para pacientes con DMD con mutaciones susceptibles al salto del exón 51, que representan aproximadamente el 13% de los casos.

Conclusiones:

  • Exondys 51 representa un avance significativo en el tratamiento de la distrofia muscular de Duchenne.
  • La aprobación subraya el potencial de las terapias genéticas dirigidas para enfermedades raras.